Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2008Expert Opinion on Emerging Drugs

Anti-infectives Clinical progress of HIV-1 integrase inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

LALaith Q. Al‐MawsawiTrillium Therapeutics (Canada)RARasha I. Al-SafiNNNouri NeamatiMichigan Medicine

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Al‐Mawsawi et al. (2008) studied this question.

synapsesocial.com/papers/6aa6e1459feada129378f4c0https://doi.org/10.1517/14728214.13.2.213
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Challenges for the Clinical Development of New Nucleoside Reverse Transcriptase Inhibitors for HIV Infection2005 · 28 citations
  2. 2Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells1992 · 261 citations
  3. 3Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga2002 · 79 citations
  4. 4Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients2000 · 562 citations